1. Angiotensin-(1-7) Treatment Early in Life Prevents Cardiac Hypertrophy in Adult Hypertensive Rats.
- Author
-
Pontes CNR, Bessa ASM, Macedo LM, Ferreira-Junior MD, Cavalcante KVN, Campos HM, Cruz-Leite VRM, Neves ÂR, Gomes RM, Ghedini PC, Biancardi MF, Mendes EP, Borges CL, Pedrino GR, and Castro CH
- Subjects
- Animals, Male, Fibrosis, Disease Models, Animal, Rats, Phosphorylation, Myocytes, Cardiac drug effects, Myocytes, Cardiac pathology, Myocytes, Cardiac metabolism, Natriuretic Peptide, Brain metabolism, Age Factors, Matrix Metalloproteinase 9 metabolism, Atrial Natriuretic Factor metabolism, Antihypertensive Agents pharmacology, Ventricular Remodeling drug effects, Angiotensin I pharmacology, Peptide Fragments pharmacology, Rats, Inbred SHR, Hypertension physiopathology, Hypertension drug therapy, Hypertension prevention & control, Cardiomegaly prevention & control, Cardiomegaly physiopathology, Cardiomegaly metabolism, Cardiomegaly drug therapy, Cardiomegaly pathology, Oxidative Stress drug effects, Blood Pressure drug effects
- Abstract
Abstract: Angiotensin (Ang)-(1-7) is a cardioprotective peptide of the renin-angiotensin system. Prepuberty has been considered as a later susceptible window of development, and stressful factors in this life phase can induce chronic diseases in adulthood. We aimed to investigate whether the treatment with Ang-(1-7) during the prepuberty could attenuate the development of hypertension and cardiac injury in adult spontaneously hypertensive rats (SHRs). SHRs were treated with Ang-(1-7) (24 μg/kg/h) from age 4 to 7 weeks. Systolic blood pressure was measured by tail-cuff plethysmography up to 17th week. Thereafter, echocardiography was performed, and the rats were euthanized for the collection of tissues and blood. Ang-(1-7) did not change the systolic blood pressure but reduced the septal and posterior wall thickness, and cardiomyocyte hypertrophy and fibrosis in SHR. In addition, Ang-(1-7) reduced the gene expression of atrial natriuretic peptide and brain natriuretic peptide, increased the metalloproteinase 9 expression, and reduced the extracellular signal-regulated kinases 1/2 phosphorylation. Ang-(1-7) also prevented the reduction of Mas receptor but did not change the protein expression of angiotensin-converting enzyme, angiotensin-converting enzyme 2, AT1, and AT2. The treatment with Ang-(1-7) decreased the malondialdehyde (MDA) levels and increased superoxide dismutase-1 and catalase activities and protein expression of catalase. Our findings demonstrate that the treatment of SHR with Ang-(1-7) for 3 weeks early in life promotes beneficial effects in the heart later in life, even without altering blood pressure, through mechanisms involving the reduction of oxidative stress and ERK1/2 phosphorylation. In addition, this study supports the prepuberty as an important programming window., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF